Dexcom Archives - Page 3 of 14 - Medical Design Sourcing

Dexcom raises awareness on World Diabetes Day

[Image courtesy of Dexcom]Dexcom (Nasdaq:DXCM) today announced its effort to raise awareness for diabetes technology on World Diabetes Day.

The continuous glucose monitor (CGM) maker aims to highlight the need to improve access to diabetes technologies. It follows Abbott and Insulet as companies look to recognize World Diabetes Day and National Diabetes Awareness Month.

Dexcom unveiled a first-of-its-kind global portrait gallery as part of its “#SeeDiabetes” initiative. It aims to offer a look at people living with diabetes from all walks of life. Australian model and Dexcom technology user Bambi Northwood Blyth serves as creative director. Portrait photographer Fernando Sippel photographed users from around the world.

The initiative features a number of notable Dexcom users. It includes musical artist and actor Nick Jonas, Grammy-winner Patti LaBelle, actor Victor Garber and more.

Get the full story at our sis…

NICE recommends automated insulin delivery tech rollout in UK, Medtronic, Dexcom applaud

The MiniMed 780G with the Guardian 4 sensor. [Image courtesy of Medtronic]An independent committee of the National Institute for Health and Care Excellence (NICE) voiced support for closed-loop insulin delivery.

The UK-based institute recommended offering automated insulin delivery (AID) for people whose type 1 diabetes is not controlled with their current device despite best possible management with an insulin pump or real-time or intermittently scanned continuous glucose monitoring (CGM).

Hybrid closed-loop systems utilize a CGM attached to the body that sends data to a body-worn insulin pump. They calculate the necessary insulin delivery to the body to keep blood glucose levels within a healthy range.

NICE, with NHS England, agreed to first offer hybrid closed-loop systems to certain people who already have an insulin pump. These include all children, young people, and women who are pregnant or planning a pregnancy. It comprises part of a five-year rollo…

Dexcom stock rises after hours on raised 2023 guidance, $500M share repurchase program

Dexcom (Nasdaq:DXCM) shares got a massive boost on third-quarter results that came in well ahead of the consensus forecast.

The San Diego-based continuous glucose monitor (CGM) maker also announced a $500 million share repurchase program in conjunction with its third-quarter results. The repurchase program follows a $1 billion senior convertible note offering this year, plus a 4-for-1 reverse stock split executed last year.

Shares of DXCM skyrocketed nearly 10% at $88.80 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down nearly 2%.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom launches next-gen G7 CGM in Canada

The G7 CGM. [Image courtesy of Dexcom]Dexcom (Nasdaq: DXCM) + today announced the commercial launch of its next-generation G7 continuous glucose monitor (CGM) in Canada.

The San Diego-based company expects to make its latest CGM technology available to Canadians on Oct. 10, 2023. It covers people with all types of diabetes aged two and older, including those who are pregnant, in the country.

G7 received FDA clearance in December 2022 and Dexcom launched the device in the U.S. in February of this year.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom, RxFood partner on AI-based nutrition, glucose monitoring for diabetes management

Within the RxFood app, Dexcom CGM users can capture photos of their meals. It eliminates the need for manual food and nutrition tracking. [Image courtesy of RxFood/Dexcom]Dexcom (Nasdaq:DXCM) announced that it teamed up with RxFood on a digital diabetes solution for people in Canada.

The first-of-its-kind partnership combines Dexcom’s continuous glucose monitoring (CGM) with RxFood’s AI-driven personalized nutrition assessments. The companies aim to introduce an improved digital health solution for people living with diabetes. It integrates food data with insulin dosing, exercise and glucose information.

RxFood made its next-generation app, featuring Dexcom CGM data integration, now available to healthcare program stakeholders in Canada. That includes clinics, hospitals, health authorities, pharmacies, insurers and employers. Through these programs, Canadians using the Dexcom G6 or G7 (once available) can access combined food and glucose data. It offer…

Dexcom One CGM sensor launches in France with reimbursement

The Dexcom One platform. [Image from Dexcom]Dexcom (Nasdaq: DXCM) + recently announced the availability of its Dexcom One real-time continuous glucose monitor (CGM) in France.

The availability of the real-time CGM sensor comes via reimbursement. It brings the technology to half a million more people with diabetes in France. The company secured access to the platform for all patients two years and older with type 1 and type 2 diabetes undergoing intensive insulin therapy.

Get the full story at our sister site, Drug Delivery Business News.

Analysts: GLP-1 drugs should have minor impact on insulin pump market — but will boost CGMs

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies could be among those affected by the rise of the GLP-1 drug class. [Images courtesy of Insulet, Medtronic and Senseonics]Based on conversations with diabetes experts, analysts are playing down the potentially negative impact of GLP-1 receptor agonists on the diabetes technology industry.

The GLP-1 drug class, which includes Ozempic and Wegovy, has cast a shadow of doubt over diabetes technology of late. This therapeutic class, a glucagon-like peptide 1, has proven to lead to improved blood sugar control and weight loss.

In addition to the popular therapeutics, some companies — like i20 Therapeutics and Vivani Medical — are developing long-term implants that elute GLP-1s.

Positive clinical results from these drugs led to some negative market movement for a few of the biggest names in diabetes technology. Analysts even recently trimmed some forecasts o…

Dexcom appoints a new board director

New Dexcom board director Rimma Driscoll. [Image from Zoetis]Dexcom (Nasdaq: DXCM) + announced today that it appointed Rimma Driscoll to its board of directors.

The San Diego-based continuous glucose monitor (CGM) maker made Driscoll’s appointment effective on Aug. 24. She currently serves as EVP and head of global strategy, commercial and business development and global biodevices for Zoetis.

At Zoetis, a leading animal health company and a Fortune 500 member, Driscoll oversees the global business strategy. She manages the execution of commercial launch plans, external business development and integration efforts.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom more than doubles profits on 25% sales growth in Q2

Dexcom (Nasdaq:DXCM) shares ticked up after hours on second-quarter results that topped the consensus forecast.

Shares of DXCM rose 2.3% at $132.35 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day down 0.6%.

The San Diego-based continuous glucose monitor (CGM) maker posted profits of $115.9 million. That equals 28¢ per share on sales of $871.3 million for the three months ended June 30, 2023.

Dexcom more than doubled its profits on sales growth of 25.2%.

Get the full story at our sister site, Drug Delivery Business News.

Dexcom CCO Teri Lawver says new sensor is ‘first step’ to expand addressable market

New Dexcom CCO Teri Lawver. [Image from Janssen Pharmaceutical Company website]Teri Lawver joined Dexcom (Nasdaq:DXCM) + as chief commercial officer just as the company got set for a massive commercial undertaking.

The FDA cleared the company’s next-generation Dexcom G7 continuous glucose monitor (CGM) in December 2022. One month later, Lawver assumed the position of CCO. Within about a month, she was set to oversee the U.S. launch of the G7.

A former Johnson & Johnson executive, Lawver became the first to serve in Dexcom’s newly created CCO role. As she assumed the position amid a crucial time for the company, she observed what makes Dexcom one of the leaders in the diabetes technology space — and potentially beyond.

“The first few months I’ve just reaffirmed the reasons that I joined Dexcom,” Lawver told Drug Delivery Business News. “It’s an unmatched opportunity for …

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]

As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a number of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came …

The biggest stories from the American Diabetes Association (ADA) 2023 Scientific Sessions

From left: the Insulet Omnipod 5, Medtronic MiniMed 780G and the Senseonics Eversense E3. These technologies were part of some of the biggest stories from the American Diabetes Associations’ 2023 Scientific Sessions. [Images courtesy of Insulet, Medtronic and Senseonics]As it does every year, this past week, the American Diabetes Association convened its Scientific Sessions to bring together leaders in the diabetes space.

At last year’s event, next-generation technologies from the big hitters took the spotlight. The 83rd iteration this past week produced a range of new studies, product updates and positive news for a range of technologies and innovations. From continuous glucose monitors (CGMs) to insulin pumps to digital platforms and diabetes reversal procedures, ADA 2023 saw it all.

Usual suspects, like Dexcom, Abbott, Medtronic and Insulet shared their updates. Meanwhile, promising data came out of Senseonics, Sernova, Bigfoot Biomedical and more.<…